AstraZeneca's Farxiga follows rival Zynquista to FDA rejection in Type 1 diabetes

15th July 2019 Uncategorised 0

The FDA’s March rejection of Sanofi and Lexicon Pharmaceuticals’ Zynquista was just a preview of what would come for the SGLT class in Type 1 diabetes. The agency shot down AstraZeneca’s Farxiga, which could have used the sales boost in the U.S.

More: AstraZeneca's Farxiga follows rival Zynquista to FDA rejection in Type 1 diabetes
Source: fierce